Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,240.00
Bid: 1,240.00
Ask: 1,245.00
Change: -37.00 (-2.90%)
Spread: 5.00 (0.403%)
Open: 1,277.00
High: 1,284.00
Low: 1,240.00
Prev. Close: 1,277.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

13 Mar 2024 13:09

RNS Number : 7313G
Indivior PLC
13 March 2024
 

March 13, 2024

Indivior PLC (the 'Company')

Annual Report and Accounts

The Company has today published on its website (www.indivior.com/en/investors) its Annual Report and Accounts for the year ended December 31, 2023 (the '2023 Annual Report').

In accordance with LR 9.6.1, the 2023 Annual Report will be submitted to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism  

A hard copy version of the 2023 Annual Report and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to shareholders who have elected to receive paper communications on or around March 28, 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

For the purposes of complying with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text is included in the 2023 Annual Report.

 

Kathryn Hudson

Company Secretary

 

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSXXLFFZXLBBBD
Date   Source Headline
28th Feb 20184:53 pmRNSHolding(s) in Company
19th Feb 20187:00 amRNSHolding(s) in Company
15th Feb 20187:00 amRNSFinal Results
14th Feb 20189:50 amRNSHolding(s) in Company
12th Feb 20183:49 pmRNSHolding(s) in Company
8th Feb 20183:27 pmRNSHolding(s) in Company
8th Feb 20187:00 amRNSIndivior asserts new patent against ANDA-filers
6th Feb 20182:14 pmRNSHolding(s) in Company
1st Feb 20187:05 amRNSTotal Voting Rights
1st Feb 20187:00 amRNSIndivior Provides Update on Tax Position
19th Jan 20187:00 amRNSNotice of Results
8th Jan 20189:24 amRNSHolding(s) in Company
4th Jan 20181:00 pmRNSJ.P. Morgan Healthcare Conference
3rd Jan 20187:00 amRNSIndivior and Addex Enter Strategic Collaboration
19th Dec 20177:00 amRNSIndivior amends and extends $534m debt facilities
12th Dec 20177:00 amRNSIndivior's RBP-7000 NDA Accepted by FDA
8th Dec 20177:00 amRNSAdditional Listing
1st Dec 20177:00 amRNSFDA Approves SUBLOCADE (TM)
23rd Nov 20171:46 pmRNSHolding(s) in Company
10th Nov 20174:02 pmRNSBlock listing Interim Review
6th Nov 20177:00 amRNSJefferies London Healthcare Conference
2nd Nov 20171:28 pmRNSBoard Committee Changes
2nd Nov 201711:40 amRNSHolding(s) in Company
2nd Nov 201711:00 amRNS3rd Quarter Results
1st Nov 20177:00 amRNSFDA Advisory Committees Vote to Approve RBP-6000
10th Oct 20177:00 amRNSNotice of Results
9th Oct 20171:17 pmRNSHolding(s) in Company
3rd Oct 20174:00 pmRNSFDA Posts Advisory Committee Notice for RBP-6000
2nd Oct 20177:00 amRNSRBP-7000 - Submission of NDA to U.S. FDA
25th Sep 20177:00 amRNSIndivior settlement with Mylan Pharmaceuticals
21st Sep 20173:36 pmRNSHolding(s) in Company
21st Sep 20179:37 amRNSHolding(s) in Company
15th Sep 20177:00 amRNSIndivior asserts new patent against ANDA-filers
11th Sep 20179:50 amRNSHolding(s) in Company
1st Sep 20173:04 pmRNSTotal Voting Rights
1st Sep 20177:00 amRNSIndivior to appeal court rulings ANDA litigation
31st Aug 20175:21 pmRNSHolding(s) in Company
30th Aug 20175:00 pmRNSMorgan Stanley Annual Global Healthcare Conference
14th Aug 20177:00 amRNSHolding(s) in Company
10th Aug 20174:36 pmRNSDirector/PDMR Shareholding (Replacement)
10th Aug 20174:00 pmRNSDirector/PDMR Shareholding
8th Aug 201711:24 amRNSHolding(s) in Company
8th Aug 201711:16 amRNSHolding(s) in Company
8th Aug 201711:14 amRNSHolding(s) in Company
8th Aug 201711:10 amRNSHolding(s) in Company
2nd Aug 201711:08 amRNSHolding(s) in Company
1st Aug 20177:00 amRNSTotal Voting Rights
31st Jul 20173:58 pmRNSHolding(s) in Company
31st Jul 20177:30 amRNSIndivior's NALSCUE® Receives ANSM MA for France
31st Jul 20177:00 amRNSRBP-6000 NDA Receives FDA Priority Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.